跳至主要内容
临床试验/NCT05134298
NCT05134298Unknown不适用

First Dose Pharmacokinetics for Piperacillin and Meropenem in ICU Patients

Karolinska University Hospital1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2019年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
50
试验地点
1
主要终点
Plasma clearance

研究概览

简要总结

The purpose of the study is to characterize the pharmacokinetics of meropenem and piperacillin in ICU-patients at the time of the first dose administration and to contrast that with the same measurements obtained in the same patient 2-3 days later during the course of ICU treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient being treated in one of the participating ICUs and planned to recieve treatment with meropenem or piperacillin.
  • Exclusion Criteria (fullfilling any exlusion criteria means that patient cannot be included in the study):
  • Not possible to retrospectively ask the patient or next of kin for consent to take part in the study or patient or next-of-kin not providing consent.
  • Not posisble to obtain and process blood samples as specified by protocol.
  • Ongoing renal replacement therapy.
  • Patient having received the same antibiotic within the previous 96 h.

排除标准

  • 未提供

研究组 & 干预措施

Study Kohort

As specified by study population, inclusion and exclusion criteria

干预措施: Piperacillin/tazobactam, Meropenem (Drug)

结局指标

主要结局

Plasma clearance

时间窗: For the first antibiotic administration and if possible for a second administration 48-72 hour later.

Plasma clearance calculated from repeated plasma concentrations measurements and pharmacokinetic modelling.

Volume of distribution

时间窗: For the first antibiotic administration and if possible for a second administration 48-72 hour later.

Apparent volume of distribution calculated from repeated plasma concentrations measurements and pharmacokinetic modelling.

次要结局

  • Plasma antibiotic concentrations at mid and end of dosing interval(For the first antibiotic administration and if possible for a second administration 48-72 hour later.)

研究者

发起方
Karolinska University Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Johan Petersson

Senior ICU consultant, Associate Professor

Karolinska University Hospital

研究点 (1)

Loading locations...

相似试验